ASGR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17256264	1.00	15/20
SCHEMBL17256267	1.00	15/20
SCHEMBL17256273	1.00	15/20
SCHEMBL17256336	1.00	15/20
SCHEMBL17256358	1.00	15/20
SCHEMBL17256362	1.00	15/20
SCHEMBL17256377	1.00	15/20
SCHEMBL17256414	1.00	15/20
SCHEMBL17256420	1.00	15/20
SCHEMBL17268897	1.00	15/20
SCHEMBL21500353	1.00	15/20
SCHEMBL21500328	0.87	15/20
SCHEMBL17256394	0.83	15/20
SCHEMBL17256421	0.80	15/20
SCHEMBL20904108	0.78	15/20
SCHEMBL29867938	0.78	15/20
SCHEMBL17268877	0.78	15/20
SCHEMBL17268894	0.78	15/20
SCHEMBL17286221	0.76	15/20
SCHEMBL17256415	0.76	15/20

Clinical trials — most relevant to ASGR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon	PHASE4	COMPLETED
Effect of Evolocumab on Vascular Function	PHASE4	COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons	PHASE4	COMPLETED
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)	PHASE3	COMPLETED
Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles	PHASE2/PHASE3	UNKNOWN
Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients	PHASE3	UNKNOWN
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer	PHASE2	RECRUITING
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC	PHASE2	RECRUITING
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers	PHASE2	COMPLETED
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection	PHASE2	UNKNOWN
GD2/CD70 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers	PHASE1	COMPLETED
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH	PHASE1	NOT_YET_RECRUITING
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer	EARLY_PHASE1	COMPLETED
SR-BI and Antiviral Treatment Response in HCV	nan	COMPLETED
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus	nan	COMPLETED
Genetic Determinants of Ankylosing Spondylitis Severity	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection	nan	NOT_YET_RECRUITING
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.	nan	RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1)	nan	COMPLETED
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile	nan	NOT_YET_RECRUITING
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus	nan	COMPLETED
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients	nan	UNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ASGR1 binder may also engage these)

Protein	Name	Similarity
Q5RBQ8	—	1.000	Q5RBQ8 →
P02706	—	0.991	P02706 →
P34927	—	0.988	P34927 →
P07307	—	0.977	P07307 →
Q8IUN9	—	0.974	Q8IUN9 →
P49301	—	0.971	P49301 →
P24721	—	0.966	P24721 →
P49300	—	0.964	P49300 →
P08290	—	0.962	P08290 →
P78380	—	0.957	P78380 →
Q9TTK7	—	0.955	Q9TTK7 →
Q9XTA8	—	0.954	Q9XTA8 →
P79391	—	0.952	P79391 →
Q8NC01	—	0.946	Q8NC01 →
Q0VCS6	—	0.945	Q0VCS6 →
Q9H9P2	—	0.945	Q9H9P2 →
Q9CXM0	—	0.944	Q9CXM0 →
P11364	—	0.943	P11364 →
Q61190	—	0.942	Q61190 →
P0DTU4	—	0.942	P0DTU4 →
Q4TU93	—	0.942	Q4TU93 →
Q3TMX7	—	0.937	Q3TMX7 →
Q9UBG0	—	0.937	Q9UBG0 →
Q6ZRP7	—	0.937	Q6ZRP7 →
Q64449	—	0.936	Q64449 →
Q14CZ8	—	0.935	Q14CZ8 →
Q8BWY2	—	0.935	Q8BWY2 →
Q6UX15	—	0.934	Q6UX15 →
O18796	—	0.934	O18796 →
P18519	—	0.934	P18519 →